EichorEICHOR
Study identifier: NCT03742037 Synced from ClinicalTrials.gov · August 04, 2026
● Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus  ·  Sponsor: Viatris Innovation GmbH

PhasePhase 2
Planned participants427
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (148)

Pinnacle Research GroupAnniston, Alabama, United States
University of California San DiegoLa Jolla, California, United States
Valerius Medical Group and Research CenterLos Alamitos, California, United States
University of Colorado School of MedicineAurora, Colorado, United States
Robert W Levin MD PAClearwater, Florida, United States
Center for Rheumatology Immunology and ArthritisFort Lauderdale, Florida, United States
Life Clinical TrialsMargate, Florida, United States
D&H National Research Centers INCMiami, Florida, United States
San Marcus Research ClinicMiami Lakes, Florida, United States
Millennium ResearchOrmond Beach, Florida, United States
Integral Rheumatology & Immunology SpecialistsPlantation, Florida, United States
Advanced Research Institute Inc Allergy & RheumatologySt. Petersburg, Florida, United States

+ 136 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →